Everafenib is a potent and blood-brain barrier (BBB) penetrant BRAF inhibitor, also inhibits MAPK signaling. Everafenib has inhibitory activity against a panel of V600E BRAF melanoma cell lines with IC 50 values of 2-10 nM, which is better than Dabrafenib ( HY-14660 ) and Vemurafenib ( HY-12057 ). Everafenib has efficacy in an intracranial mouse model of metastatic melanoma.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Raf
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.